This article is more than 5 years old. Information may no longer be current.
EULAR research targets fatigue
Click Here to Manage Email Alerts
Fatigue is a common symptom in nearly every rheumatic disease and can be difficult to address. The impact of fatigue, patient perspective, treatment approaches and assessment were among the topics surrounding fatigue that were presented at the European League Against Rheumatism Annual European Congress of Rheumatology.
Comparative research between rheumatic diseases was also conducted. Listed below are the research summaries about fatigue in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus and fibromyalgia, presented at the European League Against Rheumatism (EULAR) congress that Healio.com/Rheumatology readers found particularly interesting.
Study: Fatigue scores can be collected with minimal clinical interruption
Quantifiable fatigue scores can be collected using a brief patient questionnaire with no additional work for the physician and minimal intrusion into the clinical work flow; additionally, fatigue can be differentiated among various diseases, according to the findings of a study presented at the EULAR Annual European Congress of Rheumatology. Read more.
Fatigue scores differ between patient, physician reports in rheumatic diseases
Physicians were more likely to score patient fatigue lower than patient-reported scores among patients with rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus and fibromyalgia, according to research presented at EULAR. Read more.
Low patient satisfaction reported for fatigue-related communication, self-efficacy
Only a small number of patients with rheumatic diseases said fatigue-related communication with a rheumatologist was not important; however, less than half of patients studied were satisfied with actual communication, and more than three-quarters of patients reported that the fatigue-related communication was initiated by the patient, according to survey results. Read more.
Blisibimod may improve disease activity, fatigue and other symptoms in patients with SLE
Patients with systemic lupus erythematosus who received blisibimod showed improvements in disease activity for up to 52 weeks in a phase 2B trial, according to results presented at EULAR. Read more.
Fatigue, disease activity may predict rescue medication need in patients with RA receiving sarilumab
Disease activity and energy levels were predictive of the need for rescue medications in patients with rheumatoid arthritis who were treated with sarilumab compared with those treated with placebo, according to recently presented research. Read more.
Certain patients with Sjögren’s syndrome have higher risk for fatigue
Some patients with primary Sjögren’s syndrome were more likely to experience significant fatigue than others, according to researchers. Read more.